RxDoctor Payments Data

Reza Azizkhan, DO

Internal Medicine · Camp Hill, PANPI 1548258296

Payments from drug & device makers

$601in general payments, 2019–2025

Across 30 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$120
  • Astellas Pharma US Inc$89
  • Lilly USA, LLC$65
  • Novartis$51
  • GSK$47
  • AbbVie$32
  • plus $197 from 9 others

What the payments were for

  • Food & beverage$49783%
  • Education$10317%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$601 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$440,892
Medicare patients
767
Services billed
10,794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban145$132,248
JardianceEmpagliflozin76$82,319
JanuviaSitagliptin Phosphate73$73,914
TrulicityDulaglutide39$60,429
OzempicSemaglutide32$53,379
XareltoRivaroxaban58$48,541
MounjaroTirzepatide28$35,496
TradjentaLinagliptin35$28,576
VascepaIcosapent Ethyl33$21,152
JanumetSitagliptin Phos/Metformin Hcl19$18,694
Repatha SureclickEvolocumab14$15,789
Breo ElliptaFluticasone/Vilanterol17$12,363
Atorvastatin Calcium704$11,264
Levothyroxine Sodium900$9,629
Icosapent Ethyl15$9,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Protonix$32$137,804158 claims
Lilly USA, LLCTrulicity, Mounjaro$65$95,92467 claims
MerckJanuvia, Janumet$26$92,60892 claims
Novo NordiskOzempic$120$53,37932 claims
GSKBreo Ellipta, Arexvy, Shingrix$47$22,68955 claims
AbbVieSynthroid$32$6,293154 claims
Astellas Pharma US IncMyrbetriq$89$6,20711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Camp Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →